National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

everolimusPatient Information
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:42-O-(2-hydroxy)ethyl rapamycin
US brand name:Afinitor
Code name:RAD001



Previous:etoricoxib, Etrenol, Etretin, Eulexin, Evacet
Next:Evista, Evoxac, ex vivo-expanded HER2-specific T cells, exatecan mesylate, exemestane

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov